NKGN

NKGen Biotech, Inc. Common Stock
NKGN

Overview Fund Activity
Delisted

NKGN was delisted on the 4th of March, 2025.

Back to rankings

48 hedge funds and large institutions have $123M invested in NKGen Biotech, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 3 closing their positions.

Holders
48
Holders Change
+5
Holders Change %
+11.63%
% of All Funds
0.81%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
4
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
UOC
1
UBS O'Connor
Illinois
$3.43M
2
CSS
2
Cubist Systematic Strategies
Connecticut
$4.86M
3
CF
3
Cantor Fitzgerald
New York
$2.48M
4
Parallax Volatility Advisers
4
Parallax Volatility Advisers
California
$1.59M
5
EAM
5
Exos Asset Management
New York
$699K

Top Sellers

1
Bank of America
1
Bank of America
North Carolina
$0
2
SG
2
StoneX Group
New York
$0
3
HighTower Advisors
3
HighTower Advisors
Illinois
$313K
Name Market Value Shares Shares
Change 		Shares
Change %
SG
51
StoneX Group
New York
– – -10,000 Closed
CFGS
52
Concourse Financial Group Securities
Alabama
– – – –
1 2
3